MitoQ and Exercise Effects on Vascular Health

NCT05686967 | Active Not Recruiting Early Phase 1 DMC FDA Drug

• 2 other identifiers: 22-1521R56AG072094
• Study Type: interventional
• Target: 22
• Locations: 1 country
• Sites: 1

Brief Summary

An impairment in vascular function can lead to the development of age-associated cardiovascular disease (CVD), the leading cause of death in postmenopausal women. Regular aerobic exercise (AE) benefits vascular function in older men by reducing oxidative stress, however, similar AE training improvements are diminished or absent in postmenopausal women. not using estrogen-based hormone therapy. Vascular function and oxidative stress are improved with AE training in postmenopausal women treated with E2, suggesting an essential role of E2 in vascular adaptations to AE in women. Clinical use of E2 is contraindicated for this purpose, thus establishing alternative pharmacological approaches that could be administered as a substitute for E2 to improve AE signaling for vascular benefits and reducing CVD risk in E2-deficient postmenopausal women is biomedically important. The mitochondrial-targeted antioxidant MitoQ may be an alternative to E2 for restoring AE benefits in E2-deficient postmenopausal women given its recently established effectiveness for reducing oxidative stress and improving vascular function in that population. Accordingly, the overall aim of this application is to assess the efficacy of a 12-week randomized controlled trial of moderate intensity AE training combined with oral MitoQ (20 mg/d) compared to AE+oral placebo (PL) or No AE+MitoQ on vascular vasodilatory function (brachial artery flow-mediated dilation; FMD) in healthy E2-deficient postmenopausal women. Insight into the causes for the improvement related to molecules (e.g., nitric oxide) that promote vasodilation, mitochondrial function, oxidative stress, and the influence of "circulating factors" will also be obtained. We hypothesize that AE+MitoQ will improve both FMD \> AE+PL and \> No AE+MitoQ, and that No AE+MitoQ will improve FMD \> AE+PL. The greater improvements in endothelial function with AE+MitoQ vs. both AE+PL and No AE+MitoQ, and with No AE+MitoQ vs. AE+PL will be mediated by greater improvements in nitric oxide production, mitochondrial function, and mitochondrial and oxidative stress linked, at least in part, to changes in "circulating factors". The expected results from this study will establish the efficacy of MitoQ for restoring AE-vascular signaling in E2-deficient postmenopausal women and will provide the foundation for development of evidence-based guidelines for sex-specific AE programs for improving vascular health and preventing CVD in postmenopausal women.

Conditions

Aging; Menopause

Keywords

vascular health; exercise; oxidative stress

Outcome Measures

Primary Outcomes (1)

• Change from baseline Endothelial function at 10 weeks

  Brachial artery flow-mediated dilation

  Baseline and after 10 weeks

Other Outcomes (3)

• Change from baseline in Change in Suppression of endothelial function by mitochondrial oxidative stress at 10 weeks

  Baseline and 10 weeks

• Change from baseline in Serum exposure-induced endothelial cell reactive oxygen species production at 10 weeks

  Baseline and 10 weeks

• Change from baseline Serum exposure-induced endothelial cell nitric oxide production from at 10 weeks

  Baseline and 10 weeks

Study Arms (3)

Aerobic Exercise plus MitoQ

EXPERIMENTAL

Moderate intensity aerobic exercise, 50 minutes of treadmill exercise, 65-75% of maximal heart rate, 3 d/week for 10 weeks plus experimental MitoQ, 20mg/d. Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 10 weeks.

Dietary Supplement: MitoQ; Behavioral: Aerobic exercise

Aerobic Exercise plus Placebo

PLACEBO COMPARATOR

Moderate intensity aerobic exercise, 50 minutes of treadmill exercise, 65-75% of maximal heart rate, 3 d/week for 10 weeks plus matching placebo capsule/d for 10 weeks. Matched placebo capsules.

Dietary Supplement: Placebo; Behavioral: Aerobic exercise

No Exercise plus MitoQ

EXPERIMENTAL

No exercise plus experimental MitoQ, 20mg/d. Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 10 weeks.

Dietary Supplement: MitoQ

Interventions

MitoQ DIETARY_SUPPLEMENT

MitoQ is a biochemically modified form of ubiquinol

Also known as: Mitoquinol

Aerobic Exercise plus MitoQ; No Exercise plus MitoQ

Placebo DIETARY_SUPPLEMENT

Each placebo capsule contains inert excipient and is identical in appearance

Aerobic Exercise plus Placebo

Aerobic exercise BEHAVIORAL

Moderate intensity aerobic exercise on the treadmill

Aerobic Exercise plus MitoQ; Aerobic Exercise plus Placebo

Eligibility Criteria

• Age: 50 Years - 120 Years
• Gender Eligibility Details: Cisgender women
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• resting blood pressure \<140/90 mmHg;
• fasted glucose \<126 mg/dL;
• sedentary/recreationally active (\<2 days/wk vigorous exercise);
• healthy, as determined by medical history, physical examination, standard blood chemistries (chemistry panel, CBC and circulating thyroid levels) and ECG at rest and during exercise;
• nonsmokers;
• no use of medications that might influence cardiovascular function (i.e., antihypertensive, lipid lowering medications, blood thinners);
• no use of vitamin supplements or anti-inflammatory medications, or willing to stop 1 month prior to enrollment and for the duration of the study;
• no use of HT for at least 6 months;
• body mass index \<40kg/m2.

You may not qualify if:

• Volunteers will be excluded from the study if they have contraindications to MitoQ or AE.
• acute liver disease, history of venous thromboembolic events, preexisting or active cardiac, renal or hepatic disease, history of stomach ulcer or bleeding or epilepsy or other seizure disorder;
• diabetes, active infection, disease that affects the nervous system,
• an abnormal resting ECG, angina and/or ECG evidence of acute myocardial ischemia during the exercise test (development of ST-segment depression of more than 0.3 mV that is either horizontal, down-sloping, or slowly upsloping -less than 1 mvolt/sec and lasts more than 0.08 sec; ST elevation; chest pain or discomfort), bundle branch blocks, A-V block greater than first degree, arrhythmias;
• chronic infections;
• thyroid dysfunction, defined as an ultrasensitive TSH \<0.5 or \>5.0 mU/L; volunteers with abnormal TSH values will be re-considered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement;
• orthopedic or other problems that would interfere with participation in the exercise program
• The volunteers who choose to participate will do so with the understanding that they will be randomly assigned to study groups that involve either AE+PL (33% chance), No AE+MitoQ (33% chance) or AE+MitoQ (33% chance).

Sponsors & Collaborators

• University of Colorado, Denver: lead
• National Institute on Aging (NIA): collaborator

Study Sites (1)

University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research Laboratory

Aurora, Colorado, 80045, United States

Location

MeSH Terms

Conditions

Motor Activity

Interventions

mitoquinone; mitoquinol; Exercise

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena

Study Officials

• Kerrie L Moreau, PhD

  University of Colorado, Denver

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Participants, investigators and assessor will be blinded to MitoQ or Placebo. Participants will not be blinded to exercise or no exercise; investigators and assessor will be blinded.
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 14, 2022
• First Posted: January 17, 2023
• Study Start: January 16, 2023
• Primary Completion: September 30, 2024
• Study Completion: November 30, 2025
• Last Updated: March 25, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)